CAPRO™ Platform
Patented polymer excipient · Release by design
MORE™ Platform
Patent-pending oral wafer · OTC + Rx
Long-Acting Injectables
SubQ · IM · IA · Biodegradable implant
Home › Company

Engineering better
therapeutics.
For every patient.

Trekka Therapeutics is a biomaterial platform company commercializing two proprietary biomaterial platforms — CAPRO™ and MORE™ — built to solve the formulation problems that keep promising molecules from reaching patients. Not as a single-asset biotech. As a platform company.

Company Structure
Trekka Therapeutics, Inc.
Biomaterial platform company — Saint Paul, MN · Est. 2018
Dual Platform Engine
CAPRO™
Patented injectable & oral depot
Cleavable linker polymer · zero burst · biologic-compatible · GMP ready
Patent granted
Pre-IND FDA ✓
MORE™
Patent-pending oral wafer
Fast-dissolve sublingual · OTC + Rx · ambient stable · no water needed
Patent pending
OTC & Rx programs
Who we are

A platform company — not a single-asset biotech.

Trekka was founded on a single conviction: the formulation problems limiting most drugs are solvable — and solving them systematically with the right platform technology creates compounding value for patients, partners, and the company.

Mission
Improve how drugs are delivered — for better outcomes and broader access.
The gap between what a drug can do and what a patient actually receives is a formulation problem. Every Trekka program — whether proprietary or partnered — is designed to close that gap for a specific molecule and the patients who need it.
Vision
Platforms, not products. A platform that works for one API works for many.
Every successful program validates CAPRO™ and MORE™ more broadly — creating compounding scientific and commercial value that a single-product bet cannot replicate. The platform is the asset.
Approach
Science first. 505(b)(2) strategy built in from the very first evaluation.
Trekka doesn't separate scientific rigor from commercial strategy. Every formulation program is designed for 505(b)(2) from the first molecule evaluation — regulatory strategy is the foundation, not an afterthought.
What makes Trekka different

Four structural advantages no single competitor has all of.

These aren't positioning claims — they are architectural features of how the company, its platforms, and its commercialization model are built.

Two platforms — not one
CAPRO™ and MORE™ address different problems and combine to unlock molecules neither can deliver alone. No other drug delivery company has both.
CAPRO™ + MORE™
Dual revenue from day one
Proprietary drug programs and platform licensing run simultaneously. MORE™ OTC generates near-term revenue that funds CAPRO™ Rx development — no single-asset dependence.
Self-funding model
505(b)(2) & GMP built in
Every Rx program is designed for 505(b)(2) from evaluation. GMP processes are developed in-house today. Partners don't wait for manufacturing buildout — it's ready.
Regulatory-first
Granted patent — advancing through pre-clinical
CAPRO™ is a granted patent and MORE™ is patent-pending — the IP foundation is secure. CAPRO™ is currently in pre-clinical development; GMP manufacturing processes are being developed in parallel, ready to scale once clinical approval is obtained.
Strong IP foundation
Our story

Built from the ground up to solve what legacy platforms can't.

Trekka started with a fundamental observation — most drugs fail to reach their full potential not because of pharmacology, but because of delivery. CAPRO™ and MORE™ were built from the ground up to fix that.

The problem
40% of marketed drugs. 90% of the pipeline. All limited by delivery — not pharmacology.
Poor solubility, instability, short half-life, uncontrolled release. Legacy excipient technology — largely unchanged for decades — wasn't solving them. CAPRO™ and MORE™ were designed from the ground up to.
The science
A new polymer architecture — cleavable linkers that pre-program release at the molecular level.
Developed by Dr. Chun Wang, PhD. Functional polymer blocks + cleavable linkers eliminate burst release and acidic byproducts — the two defining limitations of PLGA.
The company
Founded 2018. Two platforms. Two revenue paths. One compounding system.
Trekka commercializes CAPRO™ and MORE™ through proprietary drug programs and platform licensing — simultaneously. MORE™ OTC generates near-term revenue while CAPRO™ Rx programs advance. Pre-IND FDA engagement complete. GMP validated.
Current pipeline
Program
Platform
Indication
Stage
Path
Melanoma Cancer Vaccine
CAPRO™ SubQ LAI · Pre-IND
CAPRO™
Oncology / Immunology
Pre-IND
NDA
LAI Pain Depot
Depot reformulation of approved analgesic
CAPRO™
Pain / Analgesia
Preclinical
505(b)(2)
Intra-oral Pain
MORE™ fast-dissolve sublingual wafer
MORE™
Pain / Consumer
Development
RxOTC
Biologic LAI — Partner
Long-acting injectable for approved biologic
CAPRO™
Autoimmune / Oncology
Evaluation
505(b)(2)
Partner programs subject to confidentiality. Additional programs under evaluation.
Leadership

The team behind the science and the strategy.

Trekka's leadership combines deep polymer science expertise and pharmaceutical development experience — built specifically to translate platform technology from lab to commercial product.

BW
President & CEO
Trekka Therapeutics, Inc. — Saint Paul, MN
Bob leads Trekka's commercial strategy, business development, and corporate operations. He brings extensive experience in pharmaceutical company formation, investor relations, and strategic partnership development — with a particular focus on translating early-stage platform technology into commercially viable drug delivery programs.

Bob oversees all partner engagement, licensing negotiations, and Trekka's dual commercialization model — managing both the proprietary program pipeline and the platform licensing business simultaneously. His work bridges the scientific foundation Dr. Wang built and the commercial partnerships needed to scale it.
Commercial strategy Business development Platform licensing Investor relations Corporate operations Strategic partnerships
CW
Chun Wang, PhD
Chief Scientific Officer
Dept. of Biomedical Engineering — University of Minnesota
Dr. Wang is the inventor of the CAPRO™ polymer excipient platform and leads all scientific and technical development at Trekka. His research at the University of Minnesota's Department of Biomedical Engineering produced CAPRO™'s distinctive functional block and cleavable linker architecture — a fundamentally new approach to controlled drug delivery that eliminates the limitations of PLGA-based systems.

Dr. Wang oversees formulation science, GMP manufacturing development, platform characterization, and Trekka's scientific advisory relationships — including the ongoing Mayo Clinic collaboration on the CAPRO™ SubQ LAI melanoma cancer vaccine program.
Polymer chemistry Formulation science Controlled release Biologic delivery GMP development CAPRO™ inventor
Scientific Advisory Board

World-class expertise in medicinal chemistry, oncology, and drug delivery.

Trekka's scientific advisors bring specialized expertise directly critical to the platform programs — guiding CAPRO™ formulation chemistry decisions, API class compatibility, and the oncology clinical strategy.

VG
Vadim Gurvich, PhD, MBA
Drug Discovery & Medicinal Chemistry
Dept. of Medicinal Chemistry & Chemical Process Development (ITDD)
University of Minnesota
Dr. Gurvich brings deep expertise in medicinal chemistry, chemical process development, and drug candidate optimization to Trekka's scientific advisory board. His background spans the full spectrum from early drug discovery through to process chemistry scale-up — the precise intersection that matters most when evaluating CAPRO™'s compatibility with novel and challenging API classes.
Role at Trekka: Guides CAPRO™ compatibility evaluation with novel API classes, advises on formulation chemistry decisions for partner molecules, and provides medicinal chemistry perspective on Trekka's 505(b)(2) program selection.
MB
Dr. Matthew Block, MD, PhD
Oncology Immunology
Department of Oncology
Mayo Clinic
Dr. Block is a leading oncology immunologist at Mayo Clinic and the clinical lead on Trekka's melanoma cancer vaccine program. His research expertise spans cancer immunotherapy, tumor microenvironment biology, and the translational science of immune checkpoint modulation — directly guiding the clinical design and scientific rationale of the CAPRO™ SubQ LAI vaccine delivery program.
Role at Trekka: Clinical lead on the CAPRO™ SubQ LAI melanoma cancer vaccine collaboration. Guides the oncology program's clinical strategy, immune response endpoints, and translational path from pre-IND through IND filing.
Trekka's scientific advisory board is structured to provide expertise directly relevant to current platform programs — medicinal chemistry and API compatibility for CAPRO™ partnership evaluation, and clinical oncology guidance for the Mayo Clinic melanoma vaccine program. Additional advisors are engaged as specific platform applications and therapeutic areas expand.
Ready to build something
with Trekka?
Proprietary programs · Platform licensing · Co-development · Custom formulation. Whether you have a molecule with a formulation challenge or a product category that deserves a better delivery format — we'd like to talk. All inquiries treated confidentially.